Development and clinical application of antibody epitope peptide vaccines for personalized tumor immunotherapy.

我使用噬菌体展示随机肽文库对MALT淋巴瘤患者提取的人重组Fab （AHSA）进行表位分析。将ahsa源性表位肽疫苗接种BALB/c小鼠，免疫后的脾细胞构建抗体Fab文库。选定的Fab克隆对目标抗原表现出与AHSA相同的反应性。而且，它们的结合亲和力比AHSA强。这些结果表明，来自抗体药物表位或模位的肽疫苗可能作为高特异性和反应性抗肿瘤抗体库的有效诱导剂。表位肽疫苗的临床应用目前正在进行中。

I performed the epitope analysis of human recombinant Fab (AHSA) retrieved from a patient with MALT lymphoma using phage display random peptide library. AHSA-derived epitope peptide vaccines were given to BALB/c mice and then antibody Fab libraries were constructed from immunized spleen cells. Selected Fab clones show the same reactivity as AHSA against target antigen. Moreover, they showed the binding affinity stronger than that of AHSA. These results suggest that peptide vaccines from the epitope or mimotope of antibody medicines may serve as a effective inducers of highly specific and reactive anti-tumor antibody repertoires. Clinical applications of epitope peptide vaccines are now in progress.